Stable and Predictable Lentiviral Vector Production at Clinical Scale.

Area of Science:

• Biotechnology
• Molecular Biology
• Gene Therapy

Background:

• Lentiviral vectors are crucial for gene therapy due to their safety and ability to transduce non-dividing cells.
• Current transient production methods for clinical-grade lentiviral vectors are not scalable or cost-effective.
• A need exists for stable, robust, and predictable lentiviral vector manufacturing solutions.

Purpose of the Study:

• To design, generate, and characterize EL1-820, a novel packaging cell line for stable lentiviral vector production.
• To enable efficient and reliable vector manufacturing for clinical applications.
• To establish a scalable and cost-effective alternative to transient production methods.

Main Methods:

• Development of the EL1-820 packaging cell line for lentiviral self-inactivating (SIN) vectors.
• Utilized Flp-recombinase-mediated cassette exchange (RMCE) for targeted integration of vector expression cassettes.
• Characterized EL1-820 producer clones for vector titers and production scalability.

Main Results:

• EL1-820 enabled stable, single-copy integration of lentiviral transfer vectors (lenti-GFP, lenti-CAR).
• Achieved comparable titers (1 × 10^7 TU/mL) to transient production in initial experiments.
• Demonstrated scalability with bioreactor harvests yielding 8-9 × 10^7 TU/mL and a total yield of 2.3 × 10^11 TU.

Conclusions:

• RMCE-based vector construct introduction facilitates stable, defined, and predictable lentiviral vector production.
• The EL1-820 cell line offers a safe and suitable platform for clinical-grade lentiviral vector manufacturing.
• This approach addresses the limitations of transient production, paving the way for improved gene therapy applications.